Abstract:Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to most of countries in the world, threatening the health and lives of many people. Unfortunately, information regarding the immunological characteristics in COVID-19 patients remains limited. Here we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes in the adaptive immune cell populations and phenotypes. In comparison to HD, the lymphocyte percentage was slightly decreased, the percentages of CD4 and CD8 T cells in lymphocytes are similar, whereas B cell percentage increased in COVID-19 patients. T cells, especially CD8 T cells, showed an enhanced expression of late activation marker CD25 and exhaustion marker PD-1. Importantly, SARS-CoV-2 induced an increased percentage of T follicular helpher (Tfh)- and germinal center B-like (GCB-like) cells in the blood. However, the parameters in COVD-19 patients remained unchanged across various age groups. Therefore, we demonstrated that the T and B cells can be activated normally and exhibit functional features. These data provide a clue that the adaptive immunity in most people could be primed to induce a significant immune response against SARS-CoV-2 infection upon receiving standard medical care. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial COVID-19 infection was excluded from clinical trial registrition. ### Funding Statement This work was supported by grants from Natural Science Foundation of China (No. 81820108017), Natural Science Foundation of China (No. 81771673), and COVID-19 special project of Xi'an Jiaotong University Foundation (xzy032020002). We thank all the doctors, nurses, public health workers, and patients for their contribution against SARS-CoV-2 infection. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All the data are available in the manuscript.

Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controls

Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS CoV 2

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Effects of toll-like receptor agonists and SARS-CoV-2 antigens on interferon (IFN) expression by peripheral blood CD3+ T cells from COVID-19 patients

The Dynamic Role of FOXP3+ Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection

Synergism of TNF- and IFN- Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

Profound Treg perturbations correlate with COVID-19 severity

Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection

Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing

Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID

Immunological inflammatory factors in patients diagnosed with COVID-19

Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19

Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID‐19

Downregulated Gene Expression Spectrum and Immune Responses Changed During the Disease Progression in Patients With COVID-19

T Regulatory Cell Subsets Do Not Restore for One Year After Acute COVID-19

The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19

Single-cell landscape of immunological responses in patients with COVID-19

Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Serum Inflammatory Factors Are Positively Correlated with the Production of Specific Antibodies in Coronavirus Disease 2019 Patients

Increased Activation Markers of Adaptive Immunity in Patients with Severe COVID-19